NOV 08, 2017
Anti-VEGF for ROP
Pediatric Ophthalmology Subspecialty Day 2016
04:18
Pediatric Ophth/Strabismus, Vitreoretinal Diseases
In this presentation from Pediatric Subspecialty Day 2016, Dr. Helen Mintz-Hittner discusses the premise that the nondestructive treatment of Zone I ROP by anti-VEGF agents is preferable to the destruction of all retina beyond the limits of Zone I. The presentation includes the benefits and risks of using anti-VEGF for ROP.